There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Clearside Biomedical (NASDAQ: CLSD) and Bluebird Bio (NASDAQ: BLUE) with bullish sentiments.
Clearside Biomedical (NASDAQ: CLSD)
In a report released today, Liana Moussatos from Wedbush maintained a Buy rating on Clearside Biomedical (NASDAQ: CLSD), with a price target of $29. The company’s shares opened today at $10.45.
According to TipRanks.com, Moussatos is a 4-star analyst with an average return of 9.9% and a 45.4% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Catabasis Pharmaceuticals, and Global Blood Therapeutics.
Currently, the analyst consensus on Clearside Biomedical is Strong Buy and the average price target is $27, representing a 158.4% upside.
In a report issued on May 31, Cowen & Co. also assigned a Buy rating to the stock.
See today’s analyst top recommended stocks >>
Bluebird Bio (NASDAQ: BLUE)
Canaccord Genuity analyst John Newman maintained a Buy rating on Bluebird Bio (NASDAQ: BLUE) today and set a price target of $250. The company’s shares opened today at $196.20.
According to TipRanks.com, Newman is a 5-star analyst with an average return of 19.5% and a 48.8% success rate. Newman covers the Healthcare sector, focusing on stocks such as Synergy Pharmaceuticals Inc, Atara Biotherapeutics, and Gemphire Therapeutics.
Currently, the analyst consensus on Bluebird Bio is Moderate Buy and the average price target is $213, representing an 8.6% upside.
In a report issued on June 4, Cowen & Co. also maintained a Buy rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
